Tag Archives: Adults

Adults With ADHD Three Times As Likely to Develop Dementia

Researchers report that ADHD adults, those adults who are suffering from attention deficit and hyperactivity disorder, are over 3 times as more likely to get a common type of degenerative dementia compared to those not having ADHD.1✅ JOURNAL REFERENCEDOI: 10.1111/j.1468-1331.2010.03064.x The researchers established the association in a study of 360 subjects having degenerative dementia and… Read More »

FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available

FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available Print this page July 2, 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg… Read More »

Medical News Today: Older adults who drink tea are less likely to be depressed

Previous research has suggested that there is a link between depression and tea drinking. Now, a new study is investigating this relationship further. Depression is common among older adults, with 7% of those over the age of 60 years reporting “major depressive disorder.” Accordingly, research is underway to identify possible causes, which include genetic predisposition,… Read More »

FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults

FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults Print this page RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy… Read More »

FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor Print this page CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food… Read More »